304 related articles for article (PubMed ID: 28616718)
1. Effect of Intrastriatal 6-OHDA Lesions on Extrastriatal Brain Structures in the Mouse.
Becker B; Demirbas M; Johann S; Zendedel A; Beyer C; Clusmann H; Haas SJ; Wree A; Tan SKH; Kipp M
Mol Neurobiol; 2018 May; 55(5):4240-4252. PubMed ID: 28616718
[TBL] [Abstract][Full Text] [Related]
2. Characterization of graded 6-Hydroxydopamine unilateral lesion in medial forebrain bundle of mice.
Cui J; Zhao D; Xu M; Li Z; Qian J; Song N; Wang J; Xie J
Sci Rep; 2024 Feb; 14(1):3721. PubMed ID: 38355892
[TBL] [Abstract][Full Text] [Related]
3. Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus.
Debeir T; Ginestet L; François C; Laurens S; Martel JC; Chopin P; Marien M; Colpaert F; Raisman-Vozari R
Exp Neurol; 2005 Jun; 193(2):444-54. PubMed ID: 15869947
[TBL] [Abstract][Full Text] [Related]
4. Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway.
Christensen AB; Sørensen JCH; Ettrup KS; Orlowski D; Bjarkam CR
Brain Res Bull; 2018 May; 139():167-173. PubMed ID: 29462643
[TBL] [Abstract][Full Text] [Related]
5. Unilateral Intrastriatal 6-Hydroxydopamine Lesion in Mice: A Closer Look into Non-Motor Phenotype and Glial Response.
Mendes-Pinheiro B; Soares-Cunha C; Marote A; Loureiro-Campos E; Campos J; Barata-Antunes S; Monteiro-Fernandes D; Santos D; Duarte-Silva S; Pinto L; José Salgado A
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768962
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat.
Healy-Stoffel M; Omar Ahmad S; Stanford JA; Levant B
Brain Res; 2014 Jul; 1574():113-9. PubMed ID: 24924804
[TBL] [Abstract][Full Text] [Related]
7. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease.
Stott SRW; Barker RA
Eur J Neurosci; 2014 Mar; 39(6):1042-1056. PubMed ID: 24372914
[TBL] [Abstract][Full Text] [Related]
8. Differential Effects of LPS and 6-OHDA on Microglia's Morphology in Rats: Implications for Inflammatory Model of Parkinson's Disease.
Parra I; Martínez I; Ramírez-García G; Tizabi Y; Mendieta L
Neurotox Res; 2020 Jan; 37(1):1-11. PubMed ID: 31478124
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Sleeman IJ; Boshoff EL; Duty S
Neuropharmacology; 2012 Dec; 63(7):1268-77. PubMed ID: 22971544
[TBL] [Abstract][Full Text] [Related]
10. Involvement of astroglial fibroblast growth factor-2 and microglia in the nigral 6-OHDA parkinsonism and a possible role of glucocorticoid hormone on the glial mediated local trophism and wound repair.
Silva C; Fuxe K; Chadi G
J Neural Transm Suppl; 2009; (73):185-202. PubMed ID: 20411778
[TBL] [Abstract][Full Text] [Related]
11. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
[TBL] [Abstract][Full Text] [Related]
12. Prolonged Dysfunction of Astrocytes and Activation of Microglia Accelerate Degeneration of Dopaminergic Neurons in the Rat Substantia Nigra and Block Compensation of Early Motor Dysfunction Induced by 6-OHDA.
Kuter K; Olech Ł; Głowacka U
Mol Neurobiol; 2018 Apr; 55(4):3049-3066. PubMed ID: 28466266
[TBL] [Abstract][Full Text] [Related]
13. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
Stayte S; Rentsch P; Li KM; Vissel B
PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
[TBL] [Abstract][Full Text] [Related]
14. Further Characterization of Intrastriatal Lipopolysaccharide Model of Parkinson's Disease in C57BL/6 Mice.
Deng I; Corrigan F; Garg S; Zhou XF; Bobrovskaya L
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299000
[TBL] [Abstract][Full Text] [Related]
15. Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine.
Rodrigues RW; Gomide VC; Chadi G
Int J Neurosci; 2001 Jul; 109(1-2):91-126. PubMed ID: 11699344
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson's disease is mediated by a reduction of inducible nitric oxide synthase.
Mori MA; Delattre AM; Carabelli B; Pudell C; Bortolanza M; Staziaki PV; Visentainer JV; Montanher PF; Del Bel EA; Ferraz AC
Nutr Neurosci; 2018 Jun; 21(5):341-351. PubMed ID: 28221817
[TBL] [Abstract][Full Text] [Related]
17. Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease.
Ip CW; Beck SK; Volkmann J
J Neural Transm (Vienna); 2015 Dec; 122(12):1633-43. PubMed ID: 26290125
[TBL] [Abstract][Full Text] [Related]
18. Extracellular Zn
Tamano H; Nishio R; Morioka H; Takeda A
Mol Neurobiol; 2019 Jan; 56(1):435-443. PubMed ID: 29705946
[TBL] [Abstract][Full Text] [Related]
19. Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
Barata-Antunes S; Teixeira FG; Mendes-Pinheiro B; Domingues AV; Vilaça-Faria H; Marote A; Silva D; Sousa RA; Salgado AJ
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422916
[TBL] [Abstract][Full Text] [Related]
20. Altered melatonin MT
Kang NH; Carriere CH; Bahna SG; Niles LP
Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
